From: Pain in castration-resistant prostate cancer with bone metastases: a qualitative study
Characteristic | Â |
---|---|
Age in years, mean [range] | 71.1 [53 - 86] |
Mean years since prostate cancer diagnosis | 7.0 |
Mean years since onset of bone metastases | 1.7 |
Cancer stage* | Â |
   Well differentiated (Gleason score 2-4) | 2 (12%) |
   Moderately differentiated (Gleason score 5-7) | 5 (29%) |
   Poorly differentiated or undifferentiated (Gleason score 8-10) | 5 (29%) |
Patient-rated overall bone pain** | Â |
   Very mild | 3 (18%) |
   Mild | 3 (18%) |
   Moderate | 8 (47%) |
   Severe | 2 (12%) |
   Very severe | 0 |
Pain relief medication *** | Â |
   Ibuprofen | 3 (18%) |
   Percocet® (acetaminophen; oxycodone hydrochloride) | 8 (47%) |
   Lortab® (acetaminophen, hydrocodone bitartrate) | 1 (6%) |
   Oxycontin® (oxycodone hydrochloride) | 5 (29%) |
   Tylenol® (acetaminophen) | 4 (24%) |
   Zometa® (Zoledronic acid) | 2 (12%) |
   Vicodin® (acetominophen, hydrocodone bitartrate) | 1 (6%) |
   Darvocet® (acetominiphen; propoxyphen hydrocholoride) | 1 (6%) |